Briefing
ASCO GU 2026: ctDNA before primary RPLND tracked retroperitoneal germ cell tumor
Among 64 patients with ctDNA drawn before primary retroperitoneal lymph node dissection, an ASCO GU 2026 analysis reported sensitivity of 88% and specificity of 85% for germ cell tumor in the non-seminoma subgroup of 37 patients; seminoma specificity could not be estimated because every seminoma specimen contained tumor.